Covance, Inc. (NYSE:CVD)

CAPS Rating: 4 out of 5

A drug development services company providing a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.

Recs

0
Player Avatar TMFBiologyFool (98.28) Submitted: 2/2/2009 11:34:23 PM : Outperform Start Price: $39.82 CVD Score: -44.87

Pharma outsourcing will benefit CROs in the long run.

Featured Broker Partners


Advertisement